Recently completed clinical trials have shown that zolendric acid, marketed as Zometa, may help prevent recurrence of early stage breast cancer and may reduce the risk of metastasis to the bone when given in addition to conventional therapies. This drug also prevents bone loss that is associated with cancer treatment. The potential benefits of zolendric acid are important and could point to a new treatment strategy that is more effective and has fewer side effects than current options.
This article communicates information about ongoing investigation of the use of zolendric acid at a high level. However, the story is brief – 405 words – and omits key details and facts about the drug and ongoing research that are needed to provide the reader a complete and informed story. It would be useful to the reader to present some of the downsides of treatment, including a potentially long and costly duration of treatment. The story also should have explained who is likely to benefit based on who was included in the trials. No independent source was interviewed; someone needed to address the researcher’s claim that the drug might someday be used in all women with breast cancer.
Cost of the drug, approximately $1,200 per treatment (including physician fees), is not mentioned in this article. Information from Zometa’s manufacturer, Novartis, indicates that the drug is given by infusion every three to four weeks. Cost-effectiveness has not been widely researched. Some studies suggests that zolendric acid is a relatively expensive therapy, as is the case for many agents used in oncology.
This article does not quantify the benefits of treatment. (Also see Evidence comments.)
This article indicates that zolendric acid has few side effects and that those are temporary and occur after the drug is administered intravenously. Ideally this information would be provided by an expert instead of from a patient interview. However, research does support the patient’s statements that zolendric acid is well-tolerated but side effects can include bone pain and a temporary but acute reaction when the drug is administered.
This article briefly mentions two recent studies that indicate zolendric acid may lower the risk of breast cancer recurrence and metastases. However, it provides no details of these and does not report other effects of the drug in counteracting bone loss that occurs from the use of traditional adjuvant therapies for breast cancer. This article indicated that length of treatment in the on-going study was 2 1/2 years. Preliminary studies have administered the drug for five years.
Only one source was interviewed – an investigator in the trials. No independent experts were interviewed for balance. The article also does not adequately document its sources. For example, the journals in which recent studies have been published were not mentioned.
This article does not describe conventional breast cancer treatments other than a brief mention of chemotherapy. The story was vague about specifics of who would likely qualify and at what point in treatment this decision would be addressed. The physician quote – ""From what we can tell right now, this could potentially be applied to all women" with breast cancer" – has not been substantiated by available research and should have been addressed by an independent expert.
This article clearly states that Zometa (zolendric acid) is being tested as a new treatment for breast cancer. It states the approved uses for the drug in treating high blood levels of calcium, often caused by cancerous tumors, and for the treatment of osteoporosis. (See Costs of Treatment comments.)
The story appropriately portrayed the research on zolendric acid for this indication as novel.
We can’t be sure if the story relied solely or largely on a news release. We do know that the story included quotes from only one researcher.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like